CN102579313A - 一种能够阻断皮肤创伤术后出现继发性色素沉着的外用液体制剂 - Google Patents
一种能够阻断皮肤创伤术后出现继发性色素沉着的外用液体制剂 Download PDFInfo
- Publication number
- CN102579313A CN102579313A CN2012100864230A CN201210086423A CN102579313A CN 102579313 A CN102579313 A CN 102579313A CN 2012100864230 A CN2012100864230 A CN 2012100864230A CN 201210086423 A CN201210086423 A CN 201210086423A CN 102579313 A CN102579313 A CN 102579313A
- Authority
- CN
- China
- Prior art keywords
- liquid preparation
- water
- skin trauma
- chromatosis
- happening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 208000014674 injury Diseases 0.000 title claims abstract description 8
- 230000008733 trauma Effects 0.000 title claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 18
- 102000019197 Superoxide Dismutase Human genes 0.000 claims abstract description 14
- 108010012715 Superoxide dismutase Proteins 0.000 claims abstract description 14
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229930194248 Licoflavone Natural products 0.000 claims abstract description 8
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims abstract description 7
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims abstract description 7
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 7
- 108090000526 Papain Proteins 0.000 claims abstract description 7
- 239000004365 Protease Substances 0.000 claims abstract description 7
- 229960000458 allantoin Drugs 0.000 claims abstract description 7
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims abstract description 7
- 229940036350 bisabolol Drugs 0.000 claims abstract description 7
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 7
- 239000011707 mineral Substances 0.000 claims abstract description 7
- 229940055729 papain Drugs 0.000 claims abstract description 7
- 235000019834 papain Nutrition 0.000 claims abstract description 7
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims abstract description 6
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 6
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 6
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 14
- 230000002980 postoperative effect Effects 0.000 claims description 12
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 10
- 241000244155 Taenia Species 0.000 claims description 8
- 241001597008 Nomeidae Species 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 239000003292 glue Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- 235000010265 sodium sulphite Nutrition 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims description 4
- 241001122767 Theaceae Species 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 230000002087 whitening effect Effects 0.000 abstract description 4
- 210000002919 epithelial cell Anatomy 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 3
- 235000017166 Bambusa arundinacea Nutrition 0.000 abstract 1
- 235000017491 Bambusa tulda Nutrition 0.000 abstract 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- 244000082204 Phyllostachys viridis Species 0.000 abstract 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 abstract 1
- 241000241413 Propolis Species 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 abstract 1
- 244000269722 Thea sinensis Species 0.000 abstract 1
- 150000001535 azelaic acid derivatives Chemical class 0.000 abstract 1
- 239000011425 bamboo Substances 0.000 abstract 1
- 230000001680 brushing effect Effects 0.000 abstract 1
- 229960001484 edetic acid Drugs 0.000 abstract 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 abstract 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 abstract 1
- 229960005150 glycerol Drugs 0.000 abstract 1
- 150000003278 haem Chemical class 0.000 abstract 1
- 239000008267 milk Substances 0.000 abstract 1
- 210000004080 milk Anatomy 0.000 abstract 1
- 235000013336 milk Nutrition 0.000 abstract 1
- 229940069949 propolis Drugs 0.000 abstract 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 abstract 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 18
- 208000027418 Wounds and injury Diseases 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 230000019612 pigmentation Effects 0.000 description 16
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 210000002752 melanocyte Anatomy 0.000 description 9
- 239000003814 drug Substances 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 102000003425 Tyrosinase Human genes 0.000 description 5
- 108060008724 Tyrosinase Proteins 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000003796 beauty Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 108010051081 dopachrome isomerase Proteins 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 238000000469 dry deposition Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 1
- PGNRLPTYNKQQDY-UHFFFAOYSA-N 2,3-dihydroxyindole Chemical compound C1=CC=C2C(O)=C(O)NC2=C1 PGNRLPTYNKQQDY-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- WRWRKDRWMURIBI-UHFFFAOYSA-M mercuric amidochloride Chemical compound N[Hg]Cl WRWRKDRWMURIBI-UHFFFAOYSA-M 0.000 description 1
- 229960000432 mercuric amidochloride Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及一种能够阻断皮肤创伤术后出现继发性色素沉着的外用液体制剂，每份液体制剂包括：赤芍、丹参、竹茹提取物、水溶性甘草黄酮、水溶性红没药醇、1000u/g木瓜蛋白酶、耐热超氧化物歧化酶(SOD)、尿囊素、壬二酸衍生物、蜂皇浆、水溶性蜂胶、乙二胺四乙酸二钠、甘油、对羟基苯甲酸乙酯钠、茶多酚、亚硫酸氢钠、余量为高矿矿泉水。将制成后的液体制剂采取各种方式使用在皮肤上，比如涂抹、喷雾、面膜纸吸附贴敷、面膜刷涂敷等。本发明具有促进血液循环，清除干涸血红素，促进上皮细胞快速生长愈合，阻断创伤术后出现继发性色素沉着，并有显著美白功效的外用液体制剂。
Description
技术领域：
本发明涉及一种医疗整形和美容领域创伤术后用于阻断继发性色素沉着的外用液体制剂。其广泛用于阻断皮肤因激光、光子、E光，液氮冷冻提取，微针介入，药物剥脱点涂，物理磨削术，烧烫伤，晒伤等创伤后及将出现的继发性色素沉着。
背景技术：
对皮肤实施激光、光子、E光、液氮冷冻提取药物剥脱等医疗整形美容项目能够快速而有效的祛除色斑，但术后脱痂会遗留不同程度和不同颜色的继发性色素沉着，俗称色素回流，色素印，返黑。目前对抑制色素沉着探索很多，但对阻断创伤术后将产生的色素沉着效果都很有限。实践证明使用熊果苷、维生素C、曲酸收效甚微而且制剂容易氧化变色，大量使用甚至会引起创伤后局部皮肤出现返黑现象。氢醌衍生物以及各种儿茶酚抑制并治疗色素沉着，但这些化合物有细胞毒性，大剂量还会引起刺激性和过敏现象，并且只能在继发性色素沉着形成后起到一定的祛除作用，并不能够阻断色素沉着的发生。甚至氯化氨基汞、过氧化氢这两种黑色素细胞毒性药物都不能够阻断人类皮肤创面愈合后出现色素沉着。医疗美容界一般建议对创面进行防晒处理，并口服维生素C和维生素E。目前，继发性色素沉着一旦形成后，需长期使用果酸、维甲酸等剥脱剂再配合上述治疗药物氢醌甚至重金属汞等细胞毒性物质来缓慢祛除遗留的色素沉着，而且在停用上述外用药物后一段时间内，色素沉着仍然会出现不同程度的反弹。医疗美容界对已经生成的色素沉着到底何时能够自行消失也持很大争议。以往对此类病症治疗均以治疗黑色素或抑制酪氨酸酶活性为主，但此理论所应用的治疗药物经过多年临床上的应用，均未获得令人满意的效果。
继发性色素沉着的产生主要是由各种原因的损伤引起正常组织与黑素细胞都被破坏，黑素细胞在黑素小体内进行黑素的生化合成，而这个过程在含铜及蛋白的酪氨酸酶、多巴异构酶(THP-2)、二羟基吲哚氧化酶的分部作用下被催化形成黑素。这些黑素颗粒大部分本应该通过表皮黑素单位不断向上转移，最终脱落于表面，排出体外。但是创伤术后脱痂的局部皮肤此时正在逐渐生长愈合，从而阻断了这部分黑素排出体外的过程。而表皮下少部分的黑素则向下运动，本应该被重新吸收或被细胞吞噬后进入血循环的这部分黑素，却因为创伤术后血红素干涸沉积，在表皮基底层沉积的血红素不易参加血液循环而干涸坏死，从而形成黑色素与红色素双重沉着。成人的色素沉着发病机理与色素的成因均和肌肤受创后的愈合速度、创伤时血红素干涸沉积、瘀血凝聚、酪氨酸酶以及多巴异构酶(THP-2)的催化、新陈代谢的速度有密切关系。而不是单纯与酪氨酸酶的活性相联系。所以，及时祛除创面的血瘀，加快皮肤愈合速度，同时抑制酪氨酸酶和多巴色素异构酶(THP-2)的活性，创伤术后将产生的色素沉着是能够被阻断的。
本发明的目的是提供能够有效地促进血液循环，清除干涸血红素，促进上皮细胞快速生长愈合，阻断创伤术后出现继发性色素沉着，并有显著美白功效的外用液体制剂。
发明内容：
本发明涉及一种能够阻断皮肤创伤术后出现继发性色素沉着的外用液体制剂，每份液体制剂包括：赤芍、丹参、竹茹提取物、水溶性甘草黄酮、水溶性红没药醇、1000u/g木瓜蛋白酶、耐热超氧化物歧化酶(SOD)、尿囊素、壬二酸衍生物、蜂皇浆、水溶性蜂胶、乙二胺四乙酸二钠、甘油、对羟基苯甲酸乙酯钠、茶多酚、亚硫酸氢钠、余量为高矿矿泉水。将制成后的液体制剂采取各种方式使用在皮肤上，比如涂抹、喷雾、面膜纸吸附贴敷、面膜刷涂敷等。
本发明中含有的赤芍、丹参、竹茹具有活血消肿，行瘀血而敛新血，收敛生肌，清除干涸血红素的作用。
本发明中含有的水溶性红没药醇、尿囊素、蜂皇浆、水溶性蜂胶、有利于皮肤再生的环境，促进上皮细胞快速生长，加速伤口愈合的作用。高矿矿泉水作为溶剂，同时也可以为创面提供快速愈合所必须的微量元素。富含锌、硒、钙、镁、钾、钠、锰、溴、偏硅酸、氨基酸等124种微量元素，其中锌元素和硒元素，对创伤愈合有重要而积极地作用。
本发明中含有的1000u/g木瓜蛋白酶、耐热超氧化物歧化酶(SOD)、水溶性甘草黄酮、壬二酸衍生物作为角质代谢愈合周期内重组人体皮肤新生角质层的同时抑制酪氨酸酶和多巴色素异构酶(THP-2)的主要成分。两种酶的使用，可重组人体皮肤新生角质层，与形成色斑的黑色素中的铜离子形成络合物，阻断黑色素的形成，并能够能有效清除氧自由基。水溶性甘草黄酮抑制酪氨酸酶活性约是曲酸的25倍，约是维生素c的80倍，同时可以抑制多巴色素异构酶(THP-2)，这一作用机制是许多美白药物所不具备的。壬二酸衍生物竞争性抑制酪氨酸酶活性，对活性高的黑色素细胞有抑制作用，还具备较强的皮肤美白作用。
具体实施方式：
下面结合实施例，对本发明作进一步的描述。
实施例1：每份液体制剂各组分的配比为：赤芍3.0％、丹参1.0％、竹茹3.0％、水溶性甘草黄酮3.0％、水溶性红没药醇0.5％、1000u/g木瓜蛋白酶1.0％、耐热超氧化物歧化酶(SOD)5.0％、尿囊素0.5％、壬二酸衍生物1.0％、蜂皇浆5.0％、水溶性蜂胶1％、乙二胺四乙酸二钠0.1％、甘油5.0％、对羟基苯甲酸乙酯钠0.3％、茶多酚0.5％、亚硫酸氢钠0.1％、余量为高矿矿泉水。女，42岁，面部实施激光祛除颧骨母斑术，创面结痂脱落后即开始涂抹使用，2-7天时脱痂后局部皮肤由粉红色转为正常肤色，使用20日停用，创面没有出现继发性色素沉着。并有显著的美白滋润皮肤的作用。
实施例2：每份液体制剂各组分的配比为：赤芍1.0％、丹参3.0％、竹茹5.0％、水溶性甘草黄酮5.0％、水溶性红没药醇0.2％、1000u/g木瓜蛋白酶0.1％、耐热超氧化物歧化酶(SOD)1％、尿囊素0.3％、壬二酸衍生物3.0％、蜂皇浆1.0％、水溶性蜂胶0.5％、乙二胺四乙酸二钠0.05％、甘油7.0％、对羟基苯甲酸乙酯钠0.5％、茶多酚0.3％、亚硫酸氢钠0.2％、余量为高矿矿泉水。女，30岁，面部实施E光祛斑嫩肤美白术。医师对有斑点的位置进行了重复提取，此部分创面结痂。其他创面接受光能量较弱，没有结痂，此部分先局部涂抹。待完全脱痂后，整脸用面膜纸吸附贴敷使用，2-4天时脱痂后局部皮肤由粉红色转为正常肤色，使用20日停用，创面没有出现继发性色素沉着。皮肤呈现白皙光泽。
Claims (3)
1.一种能够阻断皮肤创伤术后出现继发性色素沉着的外用液体制剂，其特征在于，每份液体制剂各组分的配比可以为：赤芍3.0％、丹参1.0％、竹茹3.0％、水溶性甘草黄酮3.0％、水溶性红没药醇0.5％、1000u/g木瓜蛋白酶1.0％、耐热超氧化物歧化酶(SOD)5.0％、尿囊素0.5％、壬二酸衍生物1.0％、蜂皇浆5.0％、水溶性蜂胶1％、乙二胺四乙酸二钠0.1％、甘油5.0％、对羟基苯甲酸乙酯钠0.3％、茶多酚0.5％、亚硫酸氢钠0.1％、余量为高矿矿泉水。
2.一种能够阻断皮肤创伤术后出现继发性色素沉着的外用液体制剂，其特征在于，每份液体制剂各组分的配比可以为：赤芍1.0％、丹参3.0％、竹茹5.0％、水溶性甘草黄酮5.0％、水溶性红没药醇0.2％、1000u/g木瓜蛋白酶0.1％、耐热超氧化物歧化酶(SOD)1％、尿囊素0.3％、壬二酸衍生物3.0％、蜂皇浆1.0％、水溶性蜂胶0.5％、乙二胺四乙酸二钠0.05％、甘油7.0％、对羟基苯甲酸乙酯钠0.5％、茶多酚0.3％、亚硫酸氢钠0.2％、余量为高矿矿泉水。
3.如权利要求1和2所述的一种能够阻断皮肤创伤术后出现继发性色素沉着的外用液体制剂，其特征在于，组分中的“赤芍”、“丹参”、“竹茹”是指赤芍、丹参、竹茹的提取物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100864230A CN102579313B (zh) | 2012-03-28 | 2012-03-28 | 一种能够阻断皮肤创伤术后出现继发性色素沉着的外用液体制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100864230A CN102579313B (zh) | 2012-03-28 | 2012-03-28 | 一种能够阻断皮肤创伤术后出现继发性色素沉着的外用液体制剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102579313A true CN102579313A (zh) | 2012-07-18 |
| CN102579313B CN102579313B (zh) | 2013-12-25 |
Family
ID=46468926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100864230A Expired - Fee Related CN102579313B (zh) | 2012-03-28 | 2012-03-28 | 一种能够阻断皮肤创伤术后出现继发性色素沉着的外用液体制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102579313B (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103340777A (zh) * | 2013-06-21 | 2013-10-09 | 赖辉武 | 一种祛斑霜 |
| CN104398796A (zh) * | 2014-11-04 | 2015-03-11 | 孙怡 | 一种渗出性皮肤病用湿敷剂及其制备方法 |
| CN107242983A (zh) * | 2017-06-15 | 2017-10-13 | 广州暨南生物医药研究开发基地有限公司 | 一种含艾叶黄酮的漱口水及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1569123A (zh) * | 2004-04-30 | 2005-01-26 | 成进学 | 用蛇、蜂、宏、微量元素强化中药方剂的内服功能性药剂及其生产工艺 |
| CN101837082A (zh) * | 2010-03-23 | 2010-09-22 | 胡立发 | 治疗烧伤的无疤痕中药制剂 |
-
2012
- 2012-03-28 CN CN2012100864230A patent/CN102579313B/zh not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1569123A (zh) * | 2004-04-30 | 2005-01-26 | 成进学 | 用蛇、蜂、宏、微量元素强化中药方剂的内服功能性药剂及其生产工艺 |
| CN101837082A (zh) * | 2010-03-23 | 2010-09-22 | 胡立发 | 治疗烧伤的无疤痕中药制剂 |
Non-Patent Citations (1)
| Title |
|---|
| 舒树苗 等: "美白中药与植物药的研究进展", 《国外医药-植物药分册》, vol. 22, no. 6, 31 December 2007 (2007-12-31), pages 252 - 255 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103340777A (zh) * | 2013-06-21 | 2013-10-09 | 赖辉武 | 一种祛斑霜 |
| CN104398796A (zh) * | 2014-11-04 | 2015-03-11 | 孙怡 | 一种渗出性皮肤病用湿敷剂及其制备方法 |
| CN104398796B (zh) * | 2014-11-04 | 2018-01-30 | 孙怡 | 一种渗出性皮肤病用湿敷剂及其制备方法 |
| CN107242983A (zh) * | 2017-06-15 | 2017-10-13 | 广州暨南生物医药研究开发基地有限公司 | 一种含艾叶黄酮的漱口水及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102579313B (zh) | 2013-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102525870A (zh) | 中药美容面膜 | |
| WO2014014139A1 (ko) | 2액형 타입 미용용 팩류 및 패취류 조성물 | |
| KR20110086894A (ko) | 폐각의 알카리성 분말 그리고 칼슘용액을 포함하는 피부 외용제 조성물 | |
| CN106074206B (zh) | 一种护肤主剂、制备方法及其应用 | |
| CN101647767B (zh) | 一种美白祛斑面膜用溶液及其制备方法 | |
| CA2892010A1 (en) | Compositions and methods for their dermatological use | |
| CN102258452A (zh) | 一种中药美白祛斑面膜的配方与制备方法 | |
| CN103142856A (zh) | 中药美白祛斑液 | |
| CN111012725A (zh) | 一种芦笋护肤组合物及其制备方法 | |
| CN102335107A (zh) | 山药在制备美白产品中的应用 | |
| CN102579313B (zh) | 一种能够阻断皮肤创伤术后出现继发性色素沉着的外用液体制剂 | |
| CN108498390B (zh) | 一种治疗痤疮的藏本草提取物及其制备方法与应用 | |
| CN108992389A (zh) | 一种祛痘淡斑敷料 | |
| CN102327200A (zh) | 一种美白祛斑产品及其制备方法 | |
| CN101653409A (zh) | 一种美白祛斑霜及其制备方法 | |
| CN109602682A (zh) | 一种祛斑美白美颜的中药面膜及其制备方法 | |
| CN101259149A (zh) | 治疗脚气的酊剂 | |
| CN110934810A (zh) | 一种美白祛斑霜的制备方法 | |
| CN104352400A (zh) | 一种祛斑霜 | |
| CN101647958A (zh) | 手参在抑制皮肤黑色素合成上的应用 | |
| CN108653177A (zh) | 一种用于美白祛斑的微针贴片及其制备方法 | |
| CN102475646A (zh) | 乌梅柠檬美白护肤液 | |
| CN102274315A (zh) | 一种治疗白癜风的外用药剂 | |
| CN109439473B (zh) | 一种祛斑美容皂及其制备方法 | |
| CN102641231B (zh) | 中药十二白润肤霜及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Li Guoan Document name: Notification of Decision on Request for Restoration of Right |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Li Guoan Document name: payment instructions |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Luo Fei Document name: Notice of termination of patent right |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131225 Termination date: 20210328 |